Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.
Affordable biosynthetic semaglutide works as well as brand-name versions for blood sugar and weight loss, expanding diabetes treatment access in lower-income regions.
Biosynthetic semaglutide shows comparable real-world glycemic and weight loss effectiveness to branded semaglutide in a Pakistani multicentre setting, demonstrating access-expanded GLP-1 therapy in a high-burden T2DM region. LMIC-specific evidence is critical for expanding affordable GLP-1 access.
What the study was
- Study design
- Prospective multicentre observational cohort
- Population
- T2DM patients in Pakistan; n=217; 30-week follow-up; multicenter
- Sample size
- 217
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
First real-world multicentre biosynthetic semaglutide data in LMIC; addresses access gap; n=217 limits statistical power.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.